Portal de Periódicos da CAPES

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

2015; Volume: 9; Issue: 9-10 Linguagem: Inglês

10.5489/cuaj.3098

1920-1214

Adrian Wagg, Billy Franks, Bárbara Ramos, Todd Berner,

Urinary Tract Infections Management

Antimuscarinics are the principal pharmacological treatment for overactive bladder (OAB), but frequently give rise to anticholinergic side effects, such as dry mouth, a factor leading to poor persistence. The β3-adrenoceptor agonist mirabegron is devoid of significant anticholinergic activity, while being effective in OAB. We evaluated persistence and adherence with mirabegron versus antimuscarinics over 12 months.